Naturalistic impact of second-generation antipsychotics on weight gain

Annals of Pharmacotherapy

Volumn 40, Issue 4, 2006, Pages 626-632

  Brixner, Diana I ^a,b   Said, Qayyim ^b   Corey Lisle, Patricia K ^c   Tuomari, A Vickie ^c   L'Italien, Gilbert J ^c   Stockdale, William ^b   Oderda, Gary M ^a,b  

^a Department of Pharmacotheraphy ^*  (United States)

^b UNIVERSITY OF UTAH   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

BMI; Second generation antipsychotic agents; Weight gain

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE SUCCINATE; MESORIDAZINE BESYLATE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PROCHLORPERAZINE MALEATE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; BODY MASS; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RISK; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BODY MASS INDEX; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; WEIGHT GAIN;

EID: 33646252502     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G564     Document Type: Article

References (32)

1. Moller HJ. Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot. Eur Psychiatry 2005;20:379-85.
2. Remington G, Chong SA. Conventional versus novel antipsychotics: changing concepts and clinical implications. J Psychiatry Neurosci 1999;24:431-41.
3. Shen WW. A history of antipsychotic drug development. Compr Psychiatry 1999;40:407-14.
4. Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996;57(suppl 11):40-5; discussion 46-52.
5. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999;46:1396-408.
6. Krausz M. Efficacy review of antipsychotics. Curr Med Res Opin 2002;18(suppl 3):s8-12.
7. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 1996;57 (suppl 11):68-71.
8. Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 2000;57:238-55.
9. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160:1396-404.
10. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
11. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
12. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59:1021-6.
13. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243.
14. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005;118(suppl 2):15S-22S.
15. Newcomer JW. Metabolic risk during antipsychotic treatment. Clin Ther 2004;26:1936-46.
16. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004;65(suppl 18):36-46.
17. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23. Epub 19 Sept 2005.
18. Golembiewski J, Chernin E, Chopra T. Prevention and treatment of post-operative nausea and vomiting. Am J Health Syst Pharm 2005;62:1247-60;quiz 1261-2.
19. Pijl H, Meinders AE. Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. Drug Saf 1996;14:329-42.
20. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(suppl 18):47-56.
21. Ananth J, Venkatesh R, Burgoyne K, Gadasalli R, Binford R, Gunatilake S. Atypical antipsychotic induced weight gain: pathophysiology and management. Ann Clin Psychiatry 2004;16:75-85.
22. Deen D. Metabolic syndrome: time for action. Am Fam Physician 2004;69:2875-82.
23. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
24. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels-a prospective and cross-sectional evaluation. Atherosclerosis 2002;165:285-92.
25. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002;156:1070-7.
26. Janssen I, Katzmarzyk PT, Srinivasan SR, et al. Combined influence of body mass index and waist circumference on coronary artery disease risk factors among children and adolescents. Pediatrics 2005;115:1623-30.
27. Barbui C, Lintas C, Percudani M. Head-to-head comparison of the costs of atypical antipsychotics: a systemic review. CNS Drugs 2005;19:935-50.
28. Torgersen T, Rosseland LA, Malt UF. Coding guidelines for ICD-9 section on mental disorders and reliability of chart clinical diagnoses. Acta Psychiatr Scand 1990;81:62-7.
29. Angermeyer MC, Matschinger H. Public attitudes to people with depression: have there been any changes over the last decade? J Affect Disord 2004;83:177-82.
30. Pyne JM, Kuc EJ, Schroeder PJ, Fortney JC, Edlund M, Sullivan G. Relationship between perceived stigma and depression severity. J Nerv Ment Dis 2004;192:278-83.
31. Ertugrul A, Ulug B. Perception of stigma among patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2004;39:73-7.
32. Rost K, Smith R, Matthews DB, Guise B. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med 1994;3:333-7.